KADIAN
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 17h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KADIAN is an extended-release oral capsule containing morphine sulfate for management of moderate to severe pain requiring around-the-clock opioid analgesia over extended periods. It works as a pure mu-opioid agonist, binding to opioid receptors throughout the central and peripheral nervous system to produce analgesia and sedation. The extended-release formulation delivers morphine significantly more slowly than conventional oral preparations, achieving lower peak concentrations and higher trough levels at steady state.
LOE Approaching
As KADIAN approaches loss of exclusivity with minimal remaining patent protection, the brand team will likely shift focus toward managed decline, cost optimization, and preparation for generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee
Started Dec 2006
547 enrolled
OsteoarthritisChronic Pain
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Started Dec 2006
467 enrolled
Pain
Career Relevance
Working on KADIAN offers limited long-term career growth given its approaching loss of exclusivity and declining market opportunity. Professionals joining the team should expect to develop expertise in managing mature, declining products and navigating the transition to generic competition.
Brand Manager
Worked on KADIAN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.